#1

I don’t know about everyone else, but I was not aware until recently that that Vitamin D supplementation (at least from deficiency, but potentially otherwise) results in increased levels of Klotho.

Obviously this particular RCT involved people who had a deficiency and it may be that it does not make much difference once people are not deficient, but it is interesting none the less.

7 Likes
#2

Considering that up to half of the global population is deficient, it’s a big deal.

#3

What vitamin D level do you consider deficiency, and what is the evidence for that claim? Here’s what I found. I don’t think half are deficient, that sound too high.

image
image1256×203 76.3 KB

#4

The High-Dose Vitamin D Therapy, Coimbra’s Protocol is not new.

Just ignored.

3 Likes
Cautions to Synthetic Vitamin D3
#5

I just go with figures such as this…

Vitamin D deficiency is more common than you might think. Globally, studies suggest roughly one billion¹ people are vitamin D deficient. In the US alone, 42% ² of adults are deficient, while 50%³ of children aged between one and five and 70% of children aged between six and 11 have low vitamin D stores.

Since standards for minimum amounts are fairly low, I’d say a great number of people do not have enough vitamin D.

1 Like
#6

Another study on the importance of vitamin D: it can improve arterial stiffness in overweight people

2 Likes
#7

The treatment: The monkeys then received a single injection of the klotho protein. The dose was about five times their baseline levels and brought their total levels up to roughly what they’d be expected to have at birth.

They then completed the memory test again, and this time, they identified the right compartment about 60% of the time. The monkeys were tested multiple times over the next two weeks, and the improvement was sustained.

1 Like
#8

I have MS and my neurologist has me on high dose vitamin D (and have done pulse Mavenclad two years). Complete remission - although it’s probably more the Mavenclad which is a wonder drug for MS (although very very pricey. The cost for Mavenclad oral tablet 10 mg is around $39,863 for a supply of 4 tablets , depending on the pharmacy you visit. Although, free on the NHS in the U.K. Thank goodness for the NHS)

2 Likes
#9

Why a treatment/therapy such as the Coimbra Protocol is discounted / ignored. It in not profitable and other’s have to make it go away.

How dare do you use a treatment that cost a few dollars a day.

Our investors will not like this .

1 Like
#10

Much that i accept there is not an issue with synthetic d3 it is clear you can overdose.

1 Like
#11

:joy::joy::joy: I am sorry I’ve upset the investors.

1 Like
#12

Several year ago at a Goldman Sack’s presentation. One of the people speaking, paraphrase

You do not want to invest in companies that are look for/or have cures for for diseases. You should invest in companies that have long term treatment’s. That target upper middle class, such as $30.000 per year in treatment cost for the person’s life time.

3 Likes
#13

Yes, that’s the mindset of investors. They want to make as much profit as possible and they don’t care about curing diseases (unless they have the disease!)

There is also a certain subset of investors who would actually block a cure if it impacted a treatment they were invested in. This is pure evil/greed.

3 Likes
#14

It’s disgraceful! It is a clear case of market failure. It’s like built in obsolescence with lightbulbs (but obviously much worse). I have a similar suspicion about longevity studies and their impact on retirement funds…

1 Like